Vue lecture

F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom

The committee endorsed broader use of the peptides in lightly regulated compounding pharmacies that have grown into a multibillion-dollar business.

© Andrew Mangum for The New York Times

Some F.D.A. scientists pointed out that the peptides under review had not been proven to be safe or effective, and could present risks to patients.
  •  
❌